Loading
A phase 3 trial of Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 3 interventional study registered as NCT07491445 by Revolution Medicines, Inc., with 900 participants planned, started 2026-03-09 and due to reach its primary completion in 2028-06. Interventions recorded: daraxonrasib, gemcitabine, nab-paclitaxel. Conditions listed: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Shares Covalent chemistry for the RAS mutations that still have no drug, Off-the-shelf KRAS vaccines after pancreatic cancer surgery, RASolute 302, Revolution Medicines.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, KRAS & RAS inhibitors.
Shares Covalent chemistry for the RAS mutations that still have no drug, Off-the-shelf KRAS vaccines after pancreatic cancer surgery, Revolution Medicines, KRAS & RAS inhibitors.
Shares RASolute 302, Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib.
Shares RASolute 302, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, KRAS & RAS inhibitors.
Shares Revolution Medicines, Daraxonrasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors.
Shares Revolution Medicines, Daraxonrasib, Paclitaxel / nab-paclitaxel, Gemcitabine.
Shares RASolute 302, Daraxonrasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors.